Hanmi Pharmaceutical has launched Hyalrheuma, an hyaluronic acid (HA)- based osteoarthritis injection, in the United States through Teva Pharmaceutical, its U.S. partner.

Hanmi's hyaluronic acid (HA)- based osteoarthritis injection Hyalrheuma

The Korean company signed a contract in 2014 to supply $150 million worth of Hyalrheuma to Teva for 12 years. Immediately after the conclusion of the export contract, Teva conducted phase 3 clinical trials of Hyalrheuma on 600 U.S. patients. Hanmi also passed the FDA inspection of its HA production plant, which is an integral part of receiving sales approval from the FDA. In May 2018, the FDA granted marketing authorization for the product.

Hanmi plans to supply products manufactured at its Pyeongtaek Biotechnology Plant to Teva and receive a two-digit percent royalty based on the net sales of the product.

“We will do our best to make Hyalrheuma a successful brand in the U.S. market, through close cooperation with Teva,” Hanmi Pharmaceutical CEO Woo Jong-soo said.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>